Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Opyrchal, Mateusz ^a   Salisbury, Jeffrey L ^b   Zhang, Shuya ^b   McCubrey, James ^c   Hawse, John ^b   Goetz, Mattew P ^a   Lomberk, Gwen A ^a   Haddad, Tufia ^a   Degnim, Amy ^a   Lange, Carol ^d   Ingle, James N ^a   Galanis, Evanthia ^a   D'Assoro, Antonino B ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; ESTROGEN RECEPTOR ALPHA, HUMAN; HORMONE; SMAD5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ASSAY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HORMONE RESISTANCE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; MCF 7 CELL LINE; METABOLISM; PATHOLOGY;

ANIMALS; AURORA KINASE A; BREAST NEOPLASMS; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HORMONES; HUMANS; MCF-7 CELLS; MICE; SMAD5 PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901235407     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096995     Document Type: Article

References (29)

1. Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21(1):28-34.
2. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS et al. (2009) The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. International Breast Cancer Study Group. Ann Oncol 20(8):1344-51.
3. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-47.
4. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11(4):643-58. (Pubitemid 40065543)
5. Di Leo A, Malorni L (2012) Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol 30(16):1897-900.
6. Miller WR, Larionov AA (2012) Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 19;14(1):201.
7. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-6S. (Pubitemid 38116639)
8. Dodwell D, Wardley A, Johnston S (2006) Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15(5):584-94. (Pubitemid 44509773)
9. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L et al. (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98(2):229-38. (Pubitemid 36828445)
10. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A et al. (2008) The epithelial mesenchymal transition generates cells with properties of stem cells. Cell 133(4): p. 704-15. (Pubitemid 351636299)
11. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH et al. (2009) Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS ONE 4(12): p. e8377.
12. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3): p. 259-73. (Pubitemid 46349843)
13. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA (2008) Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A 105(15):5774-9. (Pubitemid 351758448)
14. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V et al. (2013) TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123(3):1348-58.
15. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ et al. (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73(5):1635-46.
16. Chang CJ, Yang JY, Xia W, Chen CT, Xie X et al. (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF-beta-catenin signaling. Cancer Cell 19(1):86-100.
17. D'Assoro AB, Lingle WL, Salisbury JL (2002) Centrosome amplification and the development of cancer. Oncogene 21(40):6146-53.
18. Chou CH, Yang NK, Liu TY, Tai SK, Hsu DS et al. (2013) Chromosome Instability Modulated by BMI1-AURKA Signaling Drives Progression in Head and Neck Cancer. Cancer Res 73(2):953-66.
19. Goepfert TM, Moreno-Smith M, Edwards DG, Pathak S, Medina D et al. (2007) Loss of chromosomal integrity drives rat mammary tumorigenesis. Brinkley WR. Int J Cancer 120(5):985-94. (Pubitemid 46214297)
20. Staff S, Isola J, Jumppanen M, Tanner M (2010) Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep 23(2):307-12.
21. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R et al. (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16(4):260-7.
22. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL et al. (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A 101(52):18123-8. (Pubitemid 40054084)
23. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M et al. (2014) The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells. Oncogene 33(5):599-610.
24. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20:3120-32. (Pubitemid 44833560)
25. Leontovich AA, Zhang S, Quatraro C, Iankov I, Veroux PF et al. (2012) Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol 40(6):1858-64.
26. Qi W, Spier C, Liu X, Agarwal A, Cooke LS et al. (2012) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37(4):434-9.
27. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM et al. (2012) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109(8):2742-7.
28. Dhasarathy A, Kajita M, Wade PA (2007) The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 21(12):2907-18. (Pubitemid 350223504)
29. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX et al. (2010) ERalpha signaling through slug regulates E-cadherin and EMT. Shetuni B, Barsky SH. Oncogene 29(10):1451-62.